YHYutong He

Yutong He

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yutong He has a total of 85 co-authors. Here are the top co-authors by number of shared publications:

  • Daojuan Li

    12 shared publications
  • Jin Shi

    Cancer Institute in Hebei Province, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China

    12 shared publications
  • Di Liang

    Cancer Institute in Hebei Province, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China

    10 shared publications
  • Yanyu Liu

    10 shared publications
  • Xin Su

    Department of Epidemiology and Statistics, School of Public Health, Hebei Province Key Laboratory of Environment and Human Health, Hebei Medical University, Shijiazhuang, China

    8 shared publications
  • Jing Jin

    Cancer Institute in Hebei Province, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China

    6 shared publications

Latest Publications

  • Open Access

    Prognostic factors and a Cox proportional hazards model for survival in primary liver cancer

    by Bei Liu, Daojuan Li, Yanyu Liu, Zining He, Yutong He

    Aim: Accurate prognostic assessment using biochemical indices is essential for personalized management of primary liver cancer in community-level hospitals. This study aimed to construct and validate a Cox regression-based nomogram integrating these indices with clinicopathological data to predict overall survival (OS). Methods: In this retrospective study, 1,124 patients with primary liver cancer were randomly allocated in a 7:3 proportion into training and validation cohorts. Univariable and multivariate Cox proportional hazards analyses were performed to identify independent prognostic factors and establish a nomogram for predicting OS at 1, 3, and 5 years. The model’s discrimination was assessed via the concordance index (C-index) and time-dependent receiver operating characteristic (ROC) curves. Furthermore, calibration curves and decision curve analysis (DCA) were utilized to evaluate predictive agreement and clinical utility. Results: Multivariate analysis identified an elevated aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio, high alpha-fetoprotein (AFP ≥ 400 ng/mL), reduced body mass index (BMI < 18.5 kg/m2), and advanced tumor-node-metastasis (TNM) stage as independent adverse predictors for OS, while surgical resection and hepatitis history favored survival. The nomogram showed moderate discrimination, yielding C-indices of 0.678 (training cohort) and 0.659 (validation cohort), with corresponding areas under the curve (AUCs) for years 1, 3, and 5 of 0.725, 0.733, and 0.779 in the training cohort and 0.700, 0.718, and 0.750 in the validation cohort. Furthermore, the model effectively stratified patients into distinct prognostic risk groups (log-rank test P < 0.001). Conclusion: This nomogram may assist clinicians in risk stratification and survival estimation for primary liver cancer patients in primary-level healthcare settings.

  • Open Access

    Cancer survival in Hebei Province, China (2009–2018): a population-based study

    by Yanyu Liu, Daojuan Li, Siqi Wu, Bei Liu, Zining He, Yaxiong Nie, Yutong He

  • Open Access

    Metabolic Signatures for Liver Cancer Diagnosis and Mechanistic Insights: A Large‐Scale, Multicenter Study

    by Yongjie Xu, Jiachen Wang, Chunmeng Ding, Changfa Xia, Yunyong Liu, Yuanjie Zheng, Sheng Chang, Shaokai Zhang, Yutong He, Ruifang Sun, et al.

    The poor prognosis of liver cancer (LC) highlights the urgent need for more effective strategies for early detection. We conducted a large, multicenter study to develop and validate a serum metabolic signature for LC diagnosis. Using high‐throughput nanoparticle‐enhanced laser desorption/ionization mass spectrometry, we profiled serum metabolites from 1,924 participants in discovery cohort recruited across 11 clinical centers and 225 participants in independent external validation cohort from two additional centers. A nine‐metabolite signature combined with alpha‐fetoprotein achieved excellent discriminatory performance, with an AUC of 0.92 in the discovery cohort and 0.93 in the external validation cohort. The combined model also showed good sensitivity for early‐stage LC, reaching 0.85 and 0.78 in the two cohorts, respectively, and performed particularly well for hepatocellular carcinoma, with AUCs of 0.94 and 0.93. Exploratory analyses suggested potential utility for intrahepatic cholangiocarcinoma diagnosis. Mendelian randomization analysis supported a potential causal association between nicotinamide (NAM) levels and LC risk. Functional studies showed that NAM promotes LC cell proliferation, migration, and invasion, through an NAD + /SIRT1‐dependent mechanism that increases HIF1α stability and activates glycolytic and MAPK signaling. Overall, we developed a promising metabolic diagnostic signature for LC and identified NAM‐associated metabolic signaling as a potential contributor to LC progression.

  • Open Access

    Association between A Body Shape Index (ABSI) and lung cancer risk among never-smoking women in Northern China: a population-based prospective cohort study

    by Yaxiong Nie, Di Liang, Jiaai Li, Bei Liu, Yuqing Jin, Jin Shi, Siqi Wu, Yanyu Liu, Xin Su, Saijin Cui, et al.

  • Open Access

    Repurposing cepharanthine as a radiosensitizer in esophageal squamous cell carcinoma through dual metabolic intervention and direct targeting of p70s6K

    by Zhihua Hao, Xin Su, Jiantao Li, Jing Jin, Zheng Li, Zhiqiang Yan, Wenpeng Jiao, Wenjing Jiao, Yingying Wang, Chenguang Ji, et al.

    Background: Metabolic reprogramming underpins the acquisition of radioresistance in esophageal squamous cell carcinoma (ESCC); however, the specific bioenergetic vulnerabilities and direct pharmacological targets remain to be fully elucidated. This study defines a distinct metabolic phenotype conferring radioresistance and evaluates the natural alkaloid Cepharanthine (CEP) as a mechanism-driven radiosensitizer. Methods: Matched clinical cohorts of radiosensitive and radioresistant ESCC patients were analyzed using untargeted and targeted metabolomics. Bioenergetic profiling (ECAR/OCR) was performed on established isogenic radioresistant cells. The mechanistic interactions between CEP and its target were mapped via network pharmacology, surface plasmon resonance (SPR), cellular thermal shift assays (CETSA), ubiquitin-proteasomal degradation assays, and Q347A site-directed mutagenesis. In vivo efficacy was validated across human cell-derived xenografts (CDX) and immunocompetent syngeneic (AKR/C57BL/6) mouse models. Results: Clinical multi-omics revealed a "metabolic duality" in radioresistant ESCC, characterized by the concurrent hyperactivation of glycolysis and oxidative phosphorylation (OXPHOS). CEP administration disrupted this metabolic network, significantly sensitizing ESCC cells to irradiation [Dose-modifying factor at 37% survival (DMF 37 ) > 1]. Mechanistically, CEP directly engages the kinase domain of p70S6K—a structural interaction dependent on the Q347 residue—and triggers its ubiquitin-proteasomal degradation. This targeted clearance disrupts the upstream PI3K/Akt/mTOR survival axis. Genetic overexpression of wild-type p70S6K, but not the Q347A mutant, rescued the dual hypermetabolic phenotype and reinstated radioresistance. Clinically, elevated p70S6K expression correlated with poor disease-free survival and therapeutic failure. In vivo, CEP synergized with radiotherapy to suppress tumor kinetics in both CDX and syngeneic models, while concurrently enhancing CD8 + T cell infiltration in the immunocompetent microenvironment, with no observable systemic toxicity. Conclusions: Radioresistant ESCC relies on a dual hypermetabolic state driven by the PI3K/Akt/mTOR/p70S6K cascade. CEP overcomes this radioresistance by physically binding to and degrading p70S6K, thereby inducing bioenergetic exhaustion and reshaping the anti-tumor microenvironment. These findings provide a solid mechanistic rationale for translating CEP into clinical radiotherapeutic regimens.


  • Open Access

    Reproductive factors and lung cancer risk in never-smoking women: a prospective cohort study

    by Yaxiong Nie, Di Liang, Yuqing Jin, Maogang Gao, Jiaai Li, Shize Wang, Siqi Wu, Jin Shi, Yanyu Liu, Xin Su, et al.

    The association between endogenous estrogen and lung cancer in never-smoking women remains unclear. This study investigated the associations of various reproductive factors, as proxies for cumulative estrogen exposure, with lung cancer risk among never-smoking women from a lung cancer screening cohort. Associations between reproductive factors and lung cancer risk were evaluated using multivariable logistic regression and restricted cubic splines. Mediation analysis assessed the mediating role of body mass index (BMI). Subgroup analyses were stratified by baseline characteristics. Robustness was verified through propensity score matching and inverse probability of treatment weighting. The study included 155,103 never-smoking women, identifying 657 incident lung cancer cases. Early menarche (< 13 years: OR, 1.41; 95% CI, 1.06-1.87), a shorter reproductive span (≤ 32 years: OR, 1.25; 95% CI, 1.02-1.54), and parity (≥ 1) (OR, 2.02; 95% CI, 1.16-3.52) were associated with increased risk. Later age at first birth (≥ 30 years) (OR, 0.63; 95% CI, 0.41-0.98) and a history of benign breast disease (OR, 0.64; 95% CI, 0.47-0.87) were inversely associated with lung cancer risk, with age at first birth showing a non-linear dose-response relationship. Mediation analyses suggested a potential role of BMI in these associations. Stratified analyses revealed significant effect modification by age, BMI, and clinical history. Reproductive factors are associated with lung cancer risk among never-smoking women. Integrating reproductive histories into routine lung cancer screening programs will facilitate more precise risk stratification.

  • Open Access

    An interpretable ultrasound-based deep learning system for early breast cancer in a Chinese population

    by Siqi Wu, Shenwen Wang, Di Liang, Jin Shi, Xiao Shang, Liwen Zhang, Yanyu Liu, Xin Su, Yi Wang, Qian Lu, et al.

    Objectives: Current deep learning models for early breast cancer lack interpretability and multimodal integration, limiting their clinical acceptance. This study aimed to develop and evaluate a deep learning system that automates breast ultrasound evaluation to support early breast cancer detection in clinical assessment. Materials and methods: We developed BrcaDetect, which integrates ultrasound image-based deep learning predictions, Breast Imaging Reporting and Data System (BI-RADS) assessments, and demographic factors. A total of 24,762 ultrasound images from 3048 women across five hospitals were retrospectively collected. The model was trained and internally validated using 19,340 images from 2399 patients at three tertiary hospitals between January 2017 and December 2020, and externally validated using 5422 images from 649 women at two additional hospitals between January 2021 and August 2023. All lesions were confirmed by biopsy or 3-year follow-up. Model performance and its impact on the diagnostic accuracy of five radiologists were evaluated. Results: BrcaDetect outperformed image-based deep learning and demographic model, achieving an area under the curve (AUC) of 0.989 (95% confidence interval (CI): 0.979–0.999), 0.851 (95% CI: 0.819–0.884), and 0.826 (95% CI: 0.804–0.848), with corresponding sensitivities of 98.8%, 93.0%, and 71.8%. In the reader study, radiologists assisted by BrcaDetect achieved significantly higher diagnostic accuracy than unassisted reading (0.977 [95% CI: 0.967–0.986] vs. 0.919 [95% CI: 0.900–0.935]; p < 0.001). Conclusions: As an image‑level decision-support model, BrcaDetect was associated with improved radiologists’ performance and interpretability under controlled reading conditions, reducing false positives and demonstrating proof-of-concept for decision support in clinical assessment workflows. Key Points: Current deep learning models for early breast cancer lack interpretability and multimodal integration, severely limiting their clinical acceptance in practice. In a retrospective study, BrcaDetect outperformed single‑modality models across three cohorts and provided strong interpretability via Grad‑CAM and Shapley values. This article addresses the lack of interpretability and multimodal integration in deep learning models for early breast cancer, presenting BrcaDetect: explainable predictions via Grad-CAM and Shapley values may reduce diagnostic uncertainty and support clinical workflow integration as a proof-of-concept.

  • Open Access

    Spatial heterogeneity of the association between fine particulate matter and lung cancer incidence in Hebei Province

    by Ze Liu, Chang Yan, Zhiqiang Yan, Xin Su, Zheng Li, Yan-Yu Liu, Yutong He

    Background: Long-term exposure to particulate matter (PM 2.5 ) can increase the population’s risk of lung cancer incidence. This study aims to further analyze the spatial heterogeneity in the association between PM 2.5 and lung cancer incidence. Methods: This study utilized lung cancer incidence data (2015–2022), PM 2.5 concentrations, and other covariates from ten cities in Hebei Province. By comparing the Ordinary Least Squares (OLS) and Geographically Weighted Regression (GWR) models, it aimed to comprehensively assess the spatial heterogeneity in the association between PM 2.5 and lung cancer incidence. Results: For every 10 μg/m 3 increase in PM 2.5 concentration, the overall relative risk (RR) of lung cancer incidence in Hebei Province was 1.079 (95% CI: 1.054–1.104). The RR associated with each 10 μg/m³ increment in PM 2.5 varied geographically, ranging from 1.026 to 1.086 across the study area, demonstrating a spatial pattern characterized by higher RR values in the north and lower values in the south. Notably, in regions with lower baseline PM 2.5 concentrations, the same incremental increase in PM 2.5 (10 μg/m³) was associated with a greater elevation in lung cancer risk. Conclusion: The association between PM 2.5 and lung cancer incidence varies spatially across cities in Hebei Province. This suggests that, while continuing to emphasize air quality improvement in heavily polluted areas, governments and administrative authorities should also address regions with lower pollution levels. Tailored air quality management strategies and targeted allocation of healthcare resources should be implemented according to local conditions.

  • Open Access

    Inflammatory markers partially mediate the association between volatile organic compounds exposure and hyperlipidemia: a nationally representative cross-sectional study from NHANES

    by Yaxiong Nie, Zining He, Bei Liu, Jiaai Li, Yanyu Liu, Xin Su, Zhiqiang Yan, Zheng Li, Chang Yan, Qian Lu, et al.

    Background: While studies have explored associations between volatile organic compounds (VOCs) and metabolic diseases, evidence specifically linking VOCs to hyperlipidemia remains limited. This study aimed to examine the association between urinary VOC metabolites and hyperlipidemia prevalence in U.S. adults. Methods: Leveraging data from the 2011–2018 National Health and Nutrition Examination Survey (NHANES), this study employed weighted logistic regression, restricted cubic spline (RCS) models, weighted quantile sum (WQS) regression, quantile-based g-computation (qgcomp), and Bayesian kernel machine regression (BKMR) to evaluate associations of individual and mixed VOC exposures with hyperlipidemia. All models were adjusted for covariates including sex, age, race/ethnicity, poverty income ratio (PIR), education level, marital status, body mass index (BMI), smoking status, alcohol consumption, and urinary creatinine. Subgroup analyses assessed effect modifications by sex and age. Multiple-mediator analysis examined the roles of inflammatory biomarkers (white blood cell, lymphocyte, and neutrophil counts) in the association between VOC exposure and hyperlipidemia. Results: Among 1,979 included participants, weighted logistic regression identified 13 VOC metabolites significantly associated with increased hyperlipidemia risk. Subgroup analyses revealed stronger effects in females and individuals aged <60 years. The RCS model demonstrated positive linear dose–response relationships for hyperlipidemia risk with exposure to xylene, N, N-dimethylformamide, acrylonitrile, crotonaldehyde, 1,3-butadiene, and styrene. Mixture analyses showed significant positive associations via both WQS (1.312 [1.073, 1.606]) and qgcomp (1.296 [1.035, 1.623]), with N, N-dimethylformamide being primary contributor. However, BKMR detected no significant association. Multiple-mediator analysis indicated that inflammatory markers partially mediated the association between the VOC mixture and hyperlipidemia, and WBC was the leading mediator, accounting for 15.094% of the mediated effect. Conclusion: This study demonstrated significant positive associations of both individual and mixed VOC exposures with hyperlipidemia, with differential susceptibility observed in females and individuals aged <60 years. N, N-dimethylformamide contributed most to the association, and this effect was partly mediated by inflammatory biomarkers.


  • Open Access

    Targeting tumor metabolism: The dual attack of emodin on glycolysis and oxidative phosphorylation in esophageal squamous cell carcinoma

    by Xin Su, Wanyu Yang, Zhiqiang Yan, Zhihua Hao, Jing Jin, Yanyu Liu, Siqi Wu, Yutong He